Skye Bioscience, Inc. SKYE
Set alert
1.32 USD +0.04 +3.13%
At close · Nov 2
1.32 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
1.28 Day range 1.36
1.25 52-week range 12.80
- YTD
- -78.00%
- 1 year
- -89.35%
- Open
- 1.28
- Prev close
- 1.28
- Mkt cap
- 5.84M
- Vol
- 9.69K
- Avg vol
- 90.73K
- EPS
- -10.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.28
- High
- 1.36
- Forward P/E
- -2.27
- Beta
- 1.75
- Short ratio
- 10.06
- Inst. own
- 86.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 29, 2024
- 50-d avg
- 4.44
- 200-d avg
- 7.74
- 1y target
- 18.00
6M chart
Events in this range
- Aug 24, 2026Split: 1 for 8
Signals (25)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 18 hours ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| RSI: Oversold | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
Newest 20 of 25.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.00 +1263.6% upside
Now 1.32
- Target (low)
- 14.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.285 | -0.34 – -0.25 | 0.00 | 0.0% | 0 | 0.0% | 6 |
| Next quarter | -0.28 | -0.31 – -0.24 | -0.18 | -55.6% | 0 | 0.0% | 4 |
| Current year | -0.88167 | -1.26 – -0.74 | -5.07 | +82.6% | 0 | 0.0% | 6 |
| Next year | -1.14 | -1.33 – -0.95 | -0.88167 | -29.5% | 0 | 0.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| Sep 20, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 20, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 10, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 27, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jul 9, 2024 | Craig-Hallum | Initiated | — | Buy |
| Jul 1, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 17, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 23, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 12, 2024 | Oppenheimer | Initiated | — | Outperform |
| Mar 14, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 5, 2024 | Piper Sandler | Initiated | — | Overweight |